文献速递乳腺癌

一线帕妥珠单抗联合曲妥珠单抗和多西他赛治疗HER2阳性局部复发或转移性乳腺癌的初步安全性和有效性(PERUSE)

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
PubMed 文献 · Ann Oncol · 2019-01-01

PERUSE是一项正在进行中的多中心单臂IIIb期研究,评估研究者选择的紫杉烷联合帕妥珠单抗和曲妥珠单抗一线治疗HER2阳性局部复发/转移性乳腺癌的安全性和有效性。共1436例患者接受至少一剂治疗,主要终点为安全性。初步分析中位随访52个月,中位无进展生存期(PFS)为20.6个月(95%CI 18.9-22.7),总体客观缓解率(ORR)为80%(95%CI 78%-82%)。

要点

  • 紫杉醇组周围神经病变(所有级别)31% vs 多西他赛组16%,但发热性中性粒细胞减少1% vs 11%,黏膜炎14% vs 25%。
  • 总体中位PFS为20.6个月(95%CI 18.9-22.7),多西他赛、紫杉醇和白蛋白结合型紫杉醇组分别为19.6、23.0和18.1个月。
  • 总体ORR为80%(95%CI 78%-82%),多西他赛、紫杉醇和白蛋白结合型紫杉醇组分别为79%、83%和77%。

核心结论

  • PERUSE初步研究结果表明,一线帕妥珠单抗联合曲妥珠单抗和紫杉烷治疗HER2阳性局部复发/转移性乳腺癌的安全性和有效性结果与CLEOPATRA研究一致。
  • 紫杉醇似乎是多西他赛的有效替代紫杉烷骨架,提供相似的PFS和ORR,且安全性特征可预测。

研究设计与样本

  • PERUSE是一项正在进行中的多中心单臂IIIb期研究。
  • 纳入不可手术的HER2阳性晚期乳腺癌(局部复发/转移性)患者,且未接受过针对局部复发/转移性乳腺癌的系统治疗(内分泌治疗除外)。
  • 患者接受多西他赛、紫杉醇或白蛋白结合型紫杉醇联合曲妥珠单抗(负荷剂量8 mg/kg,随后6 mg/kg每3周一次)和帕妥珠单抗(负荷剂量840 mg,随后420 mg每3周一次),直至疾病进展或不可接受的毒性。
  • 主要终点为安全性;次要终点包括客观缓解率(ORR)和无进展生存期(PFS)。
  • 共1436例患者接受至少一剂治疗(初始多西他赛775例,紫杉醇589例,白蛋白结合型紫杉醇65例;7例在开始紫杉烷前中止)。

主要发现

  • 中位年龄54岁;29%的患者既往接受过曲妥珠单抗治疗。
  • 帕妥珠单抗和曲妥珠单抗的中位治疗持续时间为16个月,紫杉烷为4个月。
  • 与含多西他赛治疗相比,含紫杉醇治疗与更多神经病变相关(所有级别周围神经病变31% vs 16%),但发热性中性粒细胞减少(1% vs 11%)和黏膜炎(14% vs 25%)更少。
  • 初步分析(中位随访52个月)中,总体中位PFS为20.6个月(95%CI 18.9-22.7);多西他赛、紫杉醇和白蛋白结合型紫杉醇组分别为19.6、23.0和18.1个月。
  • 总体ORR为80%(95%CI 78%-82%);多西他赛、紫杉醇和白蛋白结合型紫杉醇组分别为79%、83%和77%。

临床怎么用

  • 作者认为,紫杉醇似乎是多西他赛的有效替代紫杉烷骨架,提供相似的PFS和ORR,且安全性特征可预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bachelot T, Ciruelos E, Schneeweiss A, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019. PMID: 30796821. doi:10.1093/annonc/mdz061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。